09 June 2025

CHOSA Oncology invites investors to upcoming presentations on our precision oncology platform

We are pleased to invite both current and prospective investors to meet our executive team at two upcoming investor events in June, where we will share the latest developments in our mission to bring precision medicine to cancer patients, and for which we are now raising capital.

Our lead asset, the Cisplatin-DRP®, is a proprietary biomarker that helps identify patients who are most likely to respond to cisplatin or carboplatin - either as monotherapy or in combination with immunotherapy. The presentations will provide insight into our recent clinical progress in collaboration with Key Opinion Leaders and commercial outlook.

Meet members of CHOSA’s top management at these events:

• Peter Buhl Jensen, CEO, will present at the Aktiespararna- Aktiedagarna in Stockholm
  📍 Location: Hotel Birger Jarl, Tulegatan 8, 113 53 Stockholm, Sverige
  📅 Date: 11 June 2025
  ⏰ Time: 13:30

• Claus Frisenberg Pedersen, CCO, will present at the Økonomisk Ugebrev’s "Investor Konference" in Copenhagen

📍 Location: Fruebjergvej 3, 2100 Østerbro, Denmark
📅 Date: 18 June 2025
⏰ Time: 15:20

ABREVIATED Terms for the Directed Issue Learn more

The Board of Directors has today resolved, based on the authorization granted by the annual general meeting on 31 May 2024, to carry out the Directed Issue in accordance with the following main terms:

• The Directed Issue comprise 1,811,894 units. Each unit consists of three (3) newly issued shares and three (3) warrants series TO2, thus in total 5,435,682 shares and 5,435,682 warrants series TO 2 will be issued.

• The subscription price is SEK 1.86 per unit, which corresponds to a subscription price of SEK 0.62 per share. The warrants are issued free of charge. The subscription price has been determined through negotiations with the subscribers. Considering the challenging capital market conditions and the fact that shareholders are offered the opportunity to subscribe for shares in the Rights Issue at the same subscription price, the Board of Directors considers the Directed Issue is made at a market-based discount.
• Through the Directed Issue, the Company will raise initially approximately SEK 3.4 million before deduction of issue costs.  

Platinum-Based Therapy, Precisely Delivered – The CHOSA Approach

Cisplatin and carboplatin are closely related platinum-based chemotherapies used in 16 different cancer indications and commonly used in the treatment of breast cancer, particularly in advanced stages. However, their clinical use is often limited by toxicity and inconsistent efficacy across patients.

CHOSA has global rights to a patented gene test identifying cancer patients most likely to benefit from treatment with cisplatin—and now supported by positive data in carboplatin as well. This tool can help clinicians and patients make more informed decisions about platinum-based chemotherapy: guiding treatment toward those with a high likelihood of response and helping avoid ineffective and potentially toxic therapy for those unlikely to benefit.

The test, based on a 205-gene Platin-DRP® signature, has previously been validated for cisplatin in two independent, blinded clinical trial datasets and in a prospective phase 2 breast cancer study. Most recently, as announced on the 9th May 2025 the same predictor was evaluated in a cohort of 20 breast cancer patients treated with carboplatin, to assess whether a cisplatin-derived signature could predict response to its sister compound. The results were statistically significant and supportive - forming the basis of CHOSA’s abstract submission to ESMO.

For additional information, contact:
Peter Buhl Jensen, CEO
Peter@chosa.bio  
+ 45 21 60 89 22

Background

Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer chemotherapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD-1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Cisplatin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer.

As previously announced CHOSA is also exploring the predictive potential of the Cisplatin-DRP not only in cisplatin-treated patients but also in those treated with carboplatin in lung cancer. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort, potentially confirming its utility across both drugs. Future research will aim to determine whether the Cisplatin-DRP can predict the effectiveness of combinations of platinum drugs with PD-1/L1 inhibitors.

CHOSA in short

CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of LiPlaCis® and the DRP®.

About Cisplatin-DRP, a test to predict if cisplatin treatment is likely to be successful

CHOSA is focused on late-stage clinical development of LiPlaCis® and its DRP® drug response predictor to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment.

Lung: The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer, especially in new neoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with cisplatin doubles. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.

Immunotherapy There is a new development that adds further value to our DRP. Cisplatin has often been shown to activate the immune system (making cold tumors hot), which makes tumors susceptible to PD1 inhibitors. This synergy is particularly important but not limited to the treatment of lung cancer, bladder cancer, and head and neck cancer. In the ever-growing PD1 inhibitor market, where competition is fierce, our company stands out with the ability to predict if cisplatin will provide synergy with PD1. This can give the PD1 selling companies a significant competitive advantage.

1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609

DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.